# Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

Study · id `cardio:ct-nct06432452` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06432452](<https://clinicaltrials.gov/study/NCT06432452>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06432452

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06432452. Randomized; triple masking; primary purpose treatment. Start 2024-11-11 (actual); primary completion 2026-06-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06432452, source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)
- Started: 2024-11-11 (actual) (ClinicalTrials.gov record NCT06432452, source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)
- Primary completion: 2026-06-15 (anticipated) (ClinicalTrials.gov record NCT06432452, source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)
- Completion: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT06432452, source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)
- Countries: Netherlands (ClinicalTrials.gov record NCT06432452, source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06432452-2024-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm
- Acronym: EDIT-CAS
- Condition: Coronary Spasm
- Intervention (Drug): Endothelin Receptor Antagonist
- Intervention (Other): Placebo control
- Lead sponsor: Radboud University Medical Center
- Lead sponsor class: OTHER
- Collaborator: UMC Utrecht
- Collaborator class: OTHER
- Collaborator: Catharina Ziekenhuis Eindhoven
- Collaborator class: OTHER
- Collaborator: Maasstad Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry lists this organization as the lead sponsor: Radboud University Medical Center (`cardio:org-radboud-university-medical-center`)
- Registry lists this organization as a collaborator: UMC Utrecht (`cardio:org-umc-utrecht`)
- Registry lists this organization as a collaborator: Maasstad Hospital (`cardio:org-maasstad-hospital`)

## Provenance

Content hash: eda870963664cbbf32d872d9e699f0a56967461e61473ebf9566ac3273916a65
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
